While Cronos Group stock won't put investors in danger as CannTrust stock would, the stock still appears absurdly overvalued at nearly 180 times sales given higher-than-expected spending and recent capacity constraints. I'm also not a fan of the US$300 million price paid for Redwood Holding Group to gain further exposure into the CBD market.